Humanized, glycoengineered type II anti-CD20 monoclonal antibody that depletes CD20+ pre-B and mature B cells with enhanced ADCC and direct cell death and reduced complement dependence, aiming to lower PR3-ANCA production and small-vessel inflammation.
Humanized, glycoengineered type II anti-CD20 IgG1 that binds CD20 on pre-B and mature B cells; Fc glycoengineering increases affinity for Fc gamma RIIIa, enhancing ADCC and phagocytosis, and induces direct, caspase-independent cell death with reduced complement dependence, leading to B-cell depletion and reduced PR3-ANCA production.
Obinutuzumab binds CD20 on B cells and kills them via enhanced ADCC (FcγRIIIa-mediated NK cell cytotoxicity), antibody-dependent phagocytosis by myeloid cells, and induction of direct, caspase-independent cell death; complement involvement is minimal.
Chimeric type I anti-CD20 monoclonal antibody that depletes CD20+ pre-B and mature B cells primarily via complement-dependent cytotoxicity and ADCC to reduce PR3-ANCA levels and downstream neutrophil-driven inflammation.
Chimeric type I anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing PR3-ANCA production and downstream neutrophil-driven inflammation.
Anti-CD20 antibody binding triggers complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP by immune effectors (e.g., NK cells, macrophages), depleting CD20+ B cells.
Radiolabeled anti-PSMA monoclonal antibody that binds PSMA on prostate cancer cells and delivers lutetium-177 beta radiation to induce DNA damage and tumor cell death.
A radiolabeled anti-PSMA monoclonal antibody that binds PSMA on prostate cancer cells and delivers lutetium-177 beta radiation, causing localized DNA damage (including double-strand breaks) and tumor cell death.
The anti-PSMA antibody delivers 177Lu beta radiation to PSMA-expressing cells, causing localized ionizing radiation–induced DNA damage (including double-strand breaks) leading to cell death (with some crossfire to nearby cells).
Radiolabeled anti-PSMA monoclonal antibody variant used for biodistribution and dosimetry assessment, delivering lutetium-177 beta radiation to PSMA-expressing tumor cells.
Radiolabeled anti-PSMA monoclonal antibody (TLX591 variant, DOTA-chelated to lutetium-177) that binds PSMA on prostate cancer cells and delivers 177Lu beta radiation at the tumor site, causing DNA damage (double-strand breaks) and cell death, with cross-fire effects to nearby PSMA-expressing cells.
Radiolabeled anti-PSMA antibody binds PSMA and delivers 177Lu beta radiation to the target cell, causing DNA double-strand breaks and cell death (with cross-fire to nearby cells).
A HER2-targeting antibody–drug conjugate consisting of a human monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin F (MMAF). It binds HER2 (ERBB2), is internalized, and releases MMAF to disrupt tubulin polymerization, leading to cell-cycle arrest and apoptosis.
HER2-targeted antibody–drug conjugate that binds HER2 (ERBB2) on tumor cells, is internalized, and releases the microtubule inhibitor monomethyl auristatin F (MMAF) via linker cleavage, inhibiting tubulin polymerization and inducing G2/M arrest and apoptosis.
The ADC binds HER2 on the tumor cell, is internalized, and releases MMAF intracellularly, inhibiting tubulin polymerization and causing G2/M arrest and apoptosis of the HER2-expressing cell.